Fierce Pharma
OCTOBER 9, 2024
GSK has agreed to pay up to $2.2 billion to resolve approximately 80,000 lawsuits brought by us | GSK has agreed to pay up to $2.2 billion to resolve approximately 80,000 lawsuits brought by users of Zantac who claimed the heartburn drug caused their cancer. The agreement frees the British pharma giant from litigating 93% of the state court cases it faced in the U.S.
PharmaVoice
OCTOBER 9, 2024
Katelyn Jetelina, well known for her newsletter “Your Local Epidemiologist,” digs into the H5N1 outbreak, the public health response and what’s next for vaccinations.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
OCTOBER 9, 2024
Amid a transformation effort under CEO Christophe Bourdon, Danish dermatology expert Leo Pharma is embarking on another round of layoffs and relocations. | Leo is closing and relocating up to 250 roles as part of the “next step” in the dermatology company’s evolving strategy, a company spokesperson told Fierce Pharma. Most jobs affected by the move are based in Leo’s home country of Denmark and span “all business areas.
MedCity News
OCTOBER 9, 2024
If you thought that Big Pharma and the PBMs were the only bad guys in the saga of unreasonably high prescription drug prices in the United States, you would be wrong. Hear who else is to blame from the CEO of Blue Shield of California. The post Video: Besides, Pharma and PBMs, Who Drives Up Drug Costs? appeared first on MedCity News.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
Fierce Pharma
OCTOBER 9, 2024
With Pfizer’s revenue and share price slumping after the drugmaker skyrocketed to new heights during the pandemic, the company’s executives will reportedly hear out activist investor Starboard Valu | Activist investor Starboard Value recently picked up a $1 billion stake in the drugmaker and will now pitch a strategy shift to top executives, the Financial Times reported.
MedCity News
OCTOBER 9, 2024
HLTH, scheduled for October 20-23 in Las Vegas, spotlights individuals across the healthcare ecosystem from high-powered executives such as the head of health technology at tech and social media giant Meta to Lenny Kravitz, who will talk about health equity. Here’s a preview of who will be speaking at HLTH, what they’ll be talking about, where and when.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
OCTOBER 9, 2024
In this episode, we’re joined by Dr. Bayo Curry-Winchell, founder of Beyond Clinical Walls and medical director of urgent care clinics at Saint Mary’s Regional Medical Center. She discusses the role unconscious bias plays in maternal health disparities and ways the healthcare industry can address the maternal health crisis. The post MedCity FemFwd: Addressing the Maternal Health Crisis with Dr.
Fierce Pharma
OCTOBER 9, 2024
A decade into reformulating Pfizer’s oral renal cell carcinoma drug Inlyta (axitinib) into a treatment that can be injected for a variety of common eye diseases, Clearside Biomedical is making sign | Clearside’s CLS-AX (axitinib injectable suspension) has aced a phase 2b trial, achieving its primary and secondary outcomes for patients with neovascular age-related macular degeneration (wet AMD).
MedCity News
OCTOBER 9, 2024
On the heels of Phase 3 data showing muscle improvement in the rare neuromuscular disease spinal muscular atrophy, Scholar Rock raised $300 million in a stock offering. U.S. and European regulatory submissions for the drug are now planned for early 2025. The post Scholar Rock Scores $300M for Regulatory Filings & Launch Plans for Neuromuscular Disease Drug appeared first on MedCity News.
Fierce Pharma
OCTOBER 9, 2024
After third-party manufacturing issues led to a December rejection of Zealand Pharma’s pediatric congenital hyperinsulinism (CHI) candidate, the Danish pharma’s latest snub seems to come down to ti | Zealand’s glucagon receptor agonist dasiglucagon has been rebuffed by the FDA once again, scrambling the company's plan to launch the hypoglycemia treatment in kids with congenital hyperinsulinism.
MedCity News
OCTOBER 9, 2024
Maven Clinic’s $125 million Series F funding round was led by StepStone Group and included participation from existing investors General Catalyst, Sequoia, Oak HC/FT, Icon Ventures, Dragoneer Investment Group and Lux Capital. The post Maven Clinic Snags $125M To Boost Fertility Program, Expand Value-Based Care Partnerships appeared first on MedCity News.
pharmaphorum
OCTOBER 9, 2024
Advancing Precision Care For All with Hakim Yadi from Closed Loop Medicine. Listen to the latest podcast episode featuring insights from a leader in the healthcare industry.
MedCity News
OCTOBER 9, 2024
No one AI technology will address everything and solve all problems, so systems should prioritize those that promise the greatest value and ROI. The post Why HCOs Need a Portfolio Management Approach to AI appeared first on MedCity News.
Pharmaceutical Technology
OCTOBER 9, 2024
City Therapeutics has announced its launch accompanied by a $135m Series A financing to lead advancements in RNAi-based medicine.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
MedCity News
OCTOBER 9, 2024
Amidst the distress caused by a cancer diagnosis, patients are left to sort through vast amounts of information, treatment options, and concerns around efficacy and side effects, while juggling other life activities. The post What We’re Still Getting Wrong in Cancer Care — Glaring Gaps in the Face of Astonishing Advancements appeared first on MedCity News.
pharmaphorum
OCTOBER 9, 2024
Sage Therapeutics stops development of dalzanemdor in Alzheimer's, a few months after pulling the plug on the drug in Parkinson's
Pharmaceutical Technology
OCTOBER 9, 2024
As a major report highlights the challenges of a struggling NHS, the call for preventative care is growing in the UK.
pharmaphorum
OCTOBER 9, 2024
Ex-Pfizer CEO and finance chief withdraw support for Starboard Value campaign seeking a change in strategy at the pharma group.
PharmaVoice
OCTOBER 9, 2024
Small biotechs are making gains with AI drug development, and their advantages may help some push ahead without Big Pharma.
PharmaTech
OCTOBER 9, 2024
Pharmaceutical Technology® Europe sat down with Hanns-Christian Mahler from ten23 health to discuss the fill/finish market and sustainability considerations for facilities.
pharmaphorum
OCTOBER 9, 2024
Zealand Pharma has suffered another setback in its bid to bring glucagon receptor agonist dasiglucagon for ultra-rare disease congenital hyperinsulinism (CHI) to the US market.For the second time in less than a year, the FDA has issued a complete response letter to the company citing the need for data on a third-party manufacturing site that had failed an earlier inspection by the agency.
PharmaTech
OCTOBER 9, 2024
Zaim Gashi, area sales manager of Steriline, discussed the evolution of aseptic processing equipment in line with current regulatory requirements at CPHI Milan.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Clarivate
OCTOBER 9, 2024
In recent years, a stream of new technologies, regulations and the pandemic served as a catalyst for creating new operating models. In-house IP departments and law firms quickly adopted home working and embraced digitalization. Now that departments have settled into these new work models, leaders have the time to tactfully readdress industry best practices and ensure their departments are performing as seamlessly as possible.
European Pharmaceutical Review
OCTOBER 9, 2024
Eli Lilly and Company has appointed Dr Thomas Fuchs as its first Chief AI Officer. He will commence the role on 21 October 2024. Dr Fuchs will direct and lead artificial intelligence (AI) initiatives across different areas the company, including clinical trials and manufacturing, according to Eli Lilly. The new role also involves work to “identify, build and manage AI and machine learning solutions to help Lilly provide medicines to patients around the world”.
Pharmaceutical Technology
OCTOBER 9, 2024
Ipsen has received the UK MHRA's approval for its Elafibranor (Iqirvo) for the treatment of primary biliary cholangitis (PBC) in adults.
PharmaTech
OCTOBER 9, 2024
Pharmaceutical Technology® Europe sat down with Vinod Tuliani, Head of Pharmaceutical Sciences at Roquette, to talk about new developments in the use of excipients in dosage forms and methods of delivery.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Pharma Marketing Network
OCTOBER 9, 2024
In the rapidly evolving landscape of pharmaceutical marketing, mobile advertising solutions have emerged as a pivotal tool for reaching both patients and healthcare professionals. With the ubiquity of smartphones and the increasing reliance on mobile technology, pharma companies are leveraging these platforms to enhance their marketing strategies. This article explores the role of mobile advertising in pharma marketing, examines strategies for engaging patients, discusses approaches to reach hea
Contrarian Sales Techniques
OCTOBER 9, 2024
AI is revolutionizing medical sales, and I’m sure you’ve seen how much easier it makes things—streamlining your workload, helping you connect with healthcare professionals, and keeping up with constant industry changes. But, with all that power, you and I need to pause and think about the ethical side of things. We’re in healthcare, and that means dealing with sensitive information and high stakes.
Pharma Marketing Network
OCTOBER 9, 2024
In the rapidly evolving pharmaceutical industry, building a robust pharma network is crucial for companies aiming to expand their influence and stay competitive. A well-connected network can facilitate the dissemination of information, enhance collaborative efforts, and ultimately drive growth. This article delves into the dynamics of pharma networks, outlines key strategies for expanding influence within the industry, and highlights the importance of leveraging relationships in pharma marketing
Contrarian Sales Techniques
OCTOBER 9, 2024
AI is no longer just a buzzword—it’s reshaping industries, including medical sales. As a sales rep, you’ve likely noticed how the landscape has evolved. With AI-powered analytics , we’re no longer shooting in the dark when it comes to identifying leads, optimizing strategies, and tracking performance. In fact, those who can master AI-driven insights are positioned to achieve greater success in their sales efforts.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Expert insights. Personalized for you.
244 
Let's personalize your content